Your session is about to expire
← Back to Search
ipilimumab for Uveal Melanoma
Study Summary
This trial is testing whether combining immunotherapy with radiation therapy is more effective than immunotherapy alone for treating uveal melanoma that has spread to the liver.
- Uveal Melanoma
- Liver Metastases
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the normal prescription for SIR-Spheres® Yttrium 90?
"SIR-Spheres® Yttrium 90 is an effective solution for previous anti-angiogenic therapy, malignant neoplasms, and cases of unresectable melanoma."
Is this research endeavor actively seeking participants?
"This trial is no longer accepting new patients, with the last modification to its posting being made on April 15th 2021. If you are still in search of a clinical trial, there are presently 1374 neoplasm metastasis studies and 765 SIR-Spheres® Yttrium 90 trials actively recruiting participants."
How many participants are engaged in this experiment?
"This clinical trial has concluded its recruitment phase, having been posted on October 10th 2016 and last updated April 15th 2021. Fortunately, there are currently 1374 studies actively enrolling patients with neoplasm metastasis and 765 trials looking for participants to try SIR-Spheres® Yttrium 90."
Could you please provide an overview of any other research that has utilized SIR-Spheres® Yttrium 90?
"SIR-Spheres® Yttrium 90 is currently being tested in 765 active trials, 86 of which are at the Phase 3 level. The bulk of them originate from Pittsburgh, Pennsylvania though 42755 other sites have opened up for clinical studies involving SIR-Spheres® Yttrium 90."
Share this study with friends
Copy Link
Messenger